UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Management and prognosis of the thalassemias

Author
Edward J Benz, Jr, MD
Section Editor
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

Management of the thalassemia syndromes can be challenging due to the numerous potential disease complications and the lack of available therapies other than transfusion and hematopoietic cell transplantation, both of which have associated morbidities and costs. This topic review discusses the approach to managing alpha and beta thalassemias, including transfusion-dependent and transfusion-independent (mild or intermediate severity) disease.

Separate topic reviews discuss other issues in the thalassemias:

Scope of the disease – (see "Public health issues in the thalassemic syndromes")

Pathophysiology – (see "Pathophysiology of alpha thalassemia" and "Pathophysiology of beta thalassemia" and "Molecular pathology of the thalassemic syndromes" and "Introduction to hemoglobin mutations")

Prenatal screening – (see "Prenatal screening and testing for hemoglobinopathy")

                                   
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Oct 16, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. http://www.thalassaemia.org.cy/uploads/1466152679tifguidelinesformanagementfinalmerged.pdf (Accessed on May 12, 2017).
  2. http://thalassemia.com/#gsc.tab=0 (Accessed on May 12, 2017).
  3. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011; 118:3479.
  4. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet 2012; 379:373.
  5. Liu C, Grossman BJ. Red blood cell transfusion for hematologic disorders. Hematology Am Soc Hematol Educ Program 2015; 2015:454.
  6. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013; 98:833.
  7. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353:1135.
  8. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol 2011; 152:512.
  9. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol 2007; 138:291.
  10. Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341:99.
  11. Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician 2009; 80:339.
  12. de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med 1979; 300:5.
  13. Carr S, Rubin L, Dixon D, et al. Intrauterine therapy for homozygous alpha-thalassemia. Obstet Gynecol 1995; 85:876.
  14. Singer ST, Styles L, Bojanowski J, et al. Changing outcome of homozygous alpha-thalassemia: cautious optimism. J Pediatr Hematol Oncol 2000; 22:539.
  15. Yi JS, Moertel CL, Baker KS. Homozygous alpha-thalassemia treated with intrauterine transfusions and unrelated donor hematopoietic cell transplantation. J Pediatr 2009; 154:766.
  16. Lee SY, Chow CB, Li CK, Chiu MC. Outcome of intensive care of homozygous alpha-thalassaemia without prior intra-uterine therapy. J Paediatr Child Health 2007; 43:546.
  17. Lücke T, Pfister S, Dürken M. Neurodevelopmental outcome and haematological course of a long-time survivor with homozygous alpha-thalassaemia: case report and review of the literature. Acta Paediatr 2005; 94:1330.
  18. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion 2007; 47:792.
  19. WOLMAN IJ. TRANSFUSION THERAPY IN COOLEY'S ANEMIA: GROWTH AND HEALTH AS RELATED TO LONG-RANGE HEMOGLOBIN LEVELS. A PROGRESS REPORT. Ann N Y Acad Sci 1964; 119:736.
  20. Propper RD, Button LN, Nathan DG. New approaches to the transfusion management of thalassemia. Blood 1980; 55:55.
  21. Piomelli S, Hart D, Graziano J, et al. Current strategies in the management of Cooley's anemia. Ann N Y Acad Sci 1985; 445:256.
  22. Cazzola M, Borgna-Pignatti C, Locatelli F, et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997; 37:135.
  23. Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 1995; 89:473.
  24. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 2011; 96:1605.
  25. Taher A, El Rassi F, Isma'eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008; 93:1584.
  26. Tony S, Daar S, Elshinawy M, et al. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores. Pediatr Hematol Oncol 2012; 29:579.
  27. Musallam KM, Cappellini MD, Taher AT. Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol 2013; 20:187.
  28. Abdelrazik AM, Elshafie SM, El Said MN, et al. Study of red blood cell alloimmunization risk factors in multiply transfused thalassemia patients: role in improving thalassemia transfusion practice in Fayoum, Egypt. Transfusion 2016; 56:2303.
  29. Datta SS, Mukherjee S, Talukder B, et al. Frequency of Red Cell Alloimmunization and Autoimmunization in Thalassemia Patients: A Report from Eastern India. Adv Hematol 2015; 2015:610931.
  30. Dhawan HK, Kumawat V, Marwaha N, et al. Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients: Study on 319 patients. Asian J Transfus Sci 2014; 8:84.
  31. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012; 159:394.
  32. Azarkeivan A, Ansari S, Ahmadi MH, et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol 2011; 28:479.
  33. Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion 2014; 54:972.
  34. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood 2000; 96:3369.
  35. Spanos T, Karageorga M, Ladis V, et al. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58:50.
  36. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L, et al. Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang 1987; 52:95.
  37. Graziano JH, Piomelli S, Hilgartner M, et al. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance. J Pediatr 1981; 99:695.
  38. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008; 111:583.
  39. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111:467.
  40. Ikeda M, Sekimoto M, Takiguchi S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg 2005; 241:208.
  41. Sok J, Su W, Hopkins MA. Portal vein thrombosis following laparoscopic splenectomy for beta-thalassemia: a case study. Surg Endosc 2001; 15:1489.
  42. http://thalassemia.com/treatment-checklist.aspx#gsc.tab=0 (Accessed on July 21, 2017).
  43. Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013; 128:281.
  44. Cogliandro T, Derchi G, Mancuso L, et al. Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown) 2008; 9:515.
  45. Carpenter JP, Roughton M, Pennell DJ, Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica 2013; 98:1368.
  46. Littera R, La Nasa G, Derchi G, et al. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 2002; 100:1516.
  47. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005; 90:452.
  48. Anthi A, Tsangaris I, Hamodraka ES, et al. Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. Blood 2012; 120:1531.
  49. Morris CR, Kim HY, Wood J, et al. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica 2013; 98:1359.
  50. Derchi G, Balocco M, Bina P, et al. Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica 2014; 99:e17.
  51. Borgna-Pignatti C, Garani MC, Forni GL, et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol 2014; 167:121.
  52. Chatterjee R, Shah FT, Davis BA, et al. Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 2012; 159:462.
  53. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003; 123:730.
  54. Otrock ZK, Azar ST, Shamseddeen WA, et al. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 2006; 85:605.
  55. Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporos Int 2010; 21:183.
  56. Bhardwaj A, Swe KM, Sinha NK, Osunkwo I. Treatment for osteoporosis in people with ß-thalassaemia. Cochrane Database Syst Rev 2016; 3:CD010429.
  57. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115:1886.
  58. Matta BN, Abbas O, Maakaron JE, et al. Leg ulcers in patients with β-thalassaemia intermedia: a single centre's experience. J Eur Acad Dermatol Venereol 2014; 28:1245.
  59. Musallam KM, Taher AT, Rachmilewitz EA. β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med 2012; 2:a013482.
  60. Aessopos A, Kati M, Tsironi M, et al. Exchange blood transfusions for the treatment of leg ulcerations in thalassemia intermedia. Haematologica 2006; 91:ECR11.
  61. Gamberini MR, Fortini M, De Sanctis V. Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. Pediatr Endocrinol Rev 2004; 2 Suppl 2:319.
  62. Adam S, Afifi H, Thomas M, et al. Quality of Life Outcomes in a Pediatric Thalassemia Population in Egypt. Hemoglobin 2017; 41:16.
  63. Tuysuz G, Tayfun F. Health-related Quality of Life and its Predictors Among Transfusion-dependent Thalassemia Patients. J Pediatr Hematol Oncol 2017; 39:332.
  64. Seyedifar M, Dorkoosh FA, Hamidieh AA, et al. Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran. Int J Hematol Oncol Stem Cell Res 2016; 10:224.
  65. Sharma S, Seth B, Jawade P, et al. Quality of Life in Children with Thalassemia and their Caregivers in India. Indian J Pediatr 2017; 84:188.
  66. Hadjidemetriou M. Thalassemia: Yesterday, Today, Tomorrow. Am J Hematol 2017; 92:490.
  67. Walpurgis K, Thomas A, Vogel M, et al. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS. Drug Test Anal 2016; 8:1152.
  68. Langdon JM, Barkataki S, Berger AE, et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol 2015; 90:8.
  69. Ear J, Huang H, Wilson T, et al. RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1. Blood 2015; 126:880.
  70. Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood 2014; 123:3864.
  71. Olivieri NF, Saunthararajah Y, Thayalasuthan V, et al. A pilot study of subcutaneous decitabine in β-thalassemia intermedia. Blood 2011; 118:2708.
  72. Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood 2013; 121:2199.
  73. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993; 328:81.
  74. Faller DV, Perrine SP. Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hematol 1995; 2:109.
  75. Witt O, Monkemeyer S, Rönndahl G, et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 2003; 101:2001.
  76. Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood 2012; 120:2945.
  77. Fucharoen S, Inati A, Siritanaratku N, et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. Br J Haematol 2013; 161:587.
  78. Inati A, Kahale M, Perrine SP, et al. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. Br J Haematol 2014; 164:456.
  79. Patthamalai P, Fuchareon S, Chaneiam N, et al. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood 2014; 123:1956.
  80. Gabbianelli M, Morsilli O, Massa A, et al. Effective erythropoiesis and HbF reactivation induced by kit ligand in beta-thalassemia. Blood 2008; 111:421.
  81. Srivastava A, Shaji RV. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica 2017; 102:214.
  82. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002; 99:1902.
  83. Rivella S, May C, Chadburn A, et al. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003; 101:2932.
  84. Persons DA, Allay ER, Sawai N, et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003; 102:506.
  85. Huo Y, McConnell SC, Ryan TM. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major. Blood 2009; 113:4763.
  86. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010; 467:318.
  87. Baum C, Düllmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101:2099.
  88. Quek L, Thein SL. Molecular therapies in beta-thalassaemia. Br J Haematol 2007; 136:353.
  89. Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431.
  90. Atweh GF, Forget BG. Clinical applications of gene therapy: anemias. In: Stem Cell Biology and Gene Therapy, esenberry PJ, Stein GS, Forget BG (Eds), John Wiley, New York 1998. p.411.
  91. Nicolini FE, Imren S, Oh IH, et al. Expression of a human beta-globin transgene in erythroid cells derived from retrovirally transduced transplantable human fetal liver and cord blood cells. Blood 2002; 100:1257.
  92. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004; 104:3445.
  93. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406:82.
  94. Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A 2008; 105:10547.
  95. Persons DA, Allay ER, Sabatino DE, et al. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. Blood 2001; 97:3275.
  96. Wilber A, Hargrove PW, Kim YS, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 2011; 117:2817.
  97. Liu Y, Yang Y, Kang X, et al. One-Step Biallelic and Scarless Correction of a β-Thalassemia Mutation in Patient-Specific iPSCs without Drug Selection. Mol Ther Nucleic Acids 2017; 6:57.
  98. Zhao HF, Abraham A, Kim YS, et al. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia. Mol Ther 2017; 25:593.
  99. Boulad F, Wang X, Qu J, et al. Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood 2014; 123:1483.
  100. https://clinicaltrials.gov/ct2/show/NCT01639690?term=NCT01639690&rank=1 (Accessed on May 12, 2017).
  101. Algiraigri AH, Wright NAM, Paolucci EO, Kassam A. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2017.
  102. Foong WC, Ho JJ, Loh CK, Viprakasit V. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Cochrane Database Syst Rev 2016; 10:CD011579.
  103. Elalfy MS, Adly AA, Ismail EA, et al. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. Eur J Haematol 2013; 91:522.
  104. Nassar AH, Usta IM, Rechdan JB, et al. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol 2006; 81:499.
  105. Jensen CE, Tuck SM, Wonke B. Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. Br J Obstet Gynaecol 1995; 102:625.
  106. Aessopos A, Karabatsos F, Farmakis D, et al. Pregnancy in patients with well-treated beta-thalassemia: outcome for mothers and newborn infants. Am J Obstet Gynecol 1999; 180:360.
  107. Thompson AA, Kim HY, Singer ST, et al. Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. Am J Hematol 2013; 88:771.
  108. ACOG Committee on Obstetrics. ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. Obstet Gynecol 2007; 109:229.
  109. Russo V, Rago A, Papa AA, Nigro G. Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in β-Thalassemia Major Patients. Ann Noninvasive Electrocardiol 2016; 21:335.